Evidence for the Decreased Expression of the Latent TGF-β Binding Protein and its Splice Form in Human Liver Tumours

Abstract

Background: Recently, a splice form of the latent TGF- β binding protein (LTBP-1) was identified in the liver lacking potential important sequences for matrix association and proteinase cleavage (LTBP-1D, -1 &#106 53). For a better understanding of the unknown (patho)physiological role, the expression levels of LTBP-1D and LTBP-1 (full length) were investigated in normal and malignant human liver on the mRNA and protein level. Methods: Normal liver (5 specimens), hepatocellular carcinoma (4 specimens) and fibrolamellar carcinoma (2 specimens) were examined by quantitative reverse transcriptionpolymerase chain reaction and immunohistochemistry, for which specific antibodies were generated. Results: The mRNA levels of LTBP-1/-1D in malignant liver tissues are decreased in comparison to normal liver - more so in HCC than in FLC. This finding was confirmed by a strong decrease of immunostaining of LTBP-1/-1D in neoplastic parenchymal cells of HCC and FLC. However, the intensity of LTBP-1 (full length) protein staining was increased in the extracellular matrix of the carcinomas, while LTBP-1D was not detectable in the matrix. Conclusion: Since TGF- β is known to be over-expressed in liver tumours, the results suggest its enhanced synthesis without binding to LTBP-1. This probably influences the availability of bioactive TGF- β in the tumour tissue. The missing matrix localization of LTBP-1D indicates that the hinge region containing a heparin-binding site is essential for the binding of LTBP-1 in the extracellular matrix. LTBP-1D may fulfil specific functions for the latency of matrix-unbound TGF- β .

• Extracellular Matrix Liver Tumours Ltbp-1 Splice Forms Tgf-BETA